Drugs / SER-262
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02830542 | Aug 2016 → May 2018 | Clostridium difficile colitis | Seres Therapeutics, Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SER-262 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02830542 ↗ |
| Modality | Other / unclassified | “SER-262 is a rationally designed, multi-strain Ecobiotic® microbiome therapeutic produced synthetically by in vitro fermentation.” NCT02830542 ↗ |
| Route | Oral | “encapsulated for oral administration” NCT02830542 ↗ |